Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | PKM | P14618 | 2/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.37 |
| ▸ | GAA | P10253 | 1/20 | 0.37 |
| ▸ | HPGD | P15428 | 3/20 | 0.35 |
| ▸ | RXRA | P19793 | 1/20 | 0.35 |
| ▸ | RXRB | P28702 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | PTK2B | Q14289 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | CXCL8 | P10145 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.32 |
| ▸ | HTT | P42858 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5850556 | 0.81 | LMNA (0.47) | LMNASMN1; SMN2PKML3MBTL1MAPK1 | |
| SCHEMBL30657703 | 0.80 | LMNA (0.67) | LMNASMN1; SMN2PKML3MBTL1MAPK1 | |
| SCHEMBL1070126 | 0.80 | LMNA (0.67) | LMNASMN1; SMN2PKML3MBTL1MAPK1 | |
| SCHEMBL17720324 | 0.77 | PKM (0.52) | LMNASMN1; SMN2PKML3MBTL1HPGD | |
| SCHEMBL27626350 | 0.75 | LMNA (0.60) | LMNASMN1; SMN2PKML3MBTL1MAPK1 | |
| SCHEMBL13467926 | 0.74 | LMNA (0.58) | LMNASMN1; SMN2PKML3MBTL1MAPK1 | |
| SCHEMBL29482311 | 0.73 | LMNA (0.67) | LMNASMN1; SMN2PKML3MBTL1MAPK1 | |
| SCHEMBL1377760 | 0.73 | LMNA (0.67) | LMNASMN1; SMN2PKML3MBTL1MAPK1 | |
| SCHEMBL2035293 | 0.70 | LMNA (0.69) | LMNASMN1; SMN2PKML3MBTL1MAPK1 | |
| SCHEMBL7038982 | 0.70 | LMNA (0.58) | LMNASMN1; SMN2PKML3MBTL1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4744667-A2 | EFFICIENT AND SCALABLE SYNTHESES OF NICOTINOYL RIBOSIDES AND REDUCED NICOTINOYL RIBOSIDES, MODIFIED DERIVATIVES THEREOF, PHOSPHORYLATED ANALOGS THEREOF, ADENYLYL DINUCLEOTIDE CONJUGATES THEREOF, AND NOVEL CRYSTALLINE FORMS THEREOF | The Queen's University Of Belfast (GB) | 2026-05-20 | — | — | EP | disclosed |
| US-20250163093-A1 | EFFICIENT AND SCALABLE SYNTHESES OF NICOTINOYL RIBOSIDES AND REDUCED NICOTINOYL RIBOSIDES, MODIFIED DERIVATIVES THEREOF, PHOSPHORYLATED ANALOGS THEREOF, ADENYLYL DINUCLEOTIDE CONJUGATES THEREOF, AND NOVEL CRYSTALLINE FORMS THEREOF | THE QUEEN'S UNIVERSITY OF BELFAST (GB) | 2025-05-22 | — | — | US | disclosed |
| CN-110662542-B | Nicotinoyl nucleosides and reduced nicotinoyl nucleosides, modified derivatives thereof, phosphorylated analogs thereof, adenosine dinucleotide conjugates thereof, and efficient and scalable synthesis of novel crystalline forms thereof | 英国贝尔法斯特女王大学 | 2025-04-08 | — | — | CN | disclosed |
| CN-119320417-A | Nicotinoyl nucleosides and reduced nicotinoyl nucleosides, modified derivatives thereof, phosphorylated analogs, adenosine dinucleotide conjugates, and efficient and scalable synthesis of novel crystalline forms | 英国贝尔法斯特女王大学 | 2025-01-17 | — | — | CN | disclosed |
| US-12195494-B2 | Efficient and scalable syntheses of nicotinoyl ribosides and reduced nicotinoyl ribosides, modified derivatives thereof, phosphorylated analogs thereof, adenylyl dinucleotide conjugates thereof, and novel crystalline forms thereof | THE QUEEN'S UNIVERSITY OF BELFAST (GB) | 2025-01-14 | — | — | US | disclosed |
| US-20230391815-A1 | EFFICIENT AND SCALABLE SYNTHESES OF NICOTINOYL RIBOSIDES AND REDUCED NICOTINOYL RIBOSIDES, MODIFIED DERIVATIVES THEREOF, PHOSPHORYLATED ANALOGS THEREOF, ADENYLYL DINUCLEOTIDE CONJUGATES THEREOF, AND NOVEL CRYSTALLINE FORMS THEREOF | THE QUEEN'S UNIVERSITY OF BELFAST (GB) | 2023-12-07 | — | — | US | disclosed |
| US-11345720-B2 | Efficient and scalable syntheses of nicotinoyl ribosides and reduced nicotinoyl ribosides, modified derivatives thereof, phosphorylated analogs thereof, adenylyl dinucleotide conjugates thereof, and novel crystalline forms thereof | THE QUEEN'S UNIVERSITY OF BELFAST (GB) | 2022-05-31 | — | — | US | disclosed |
| US-20220106350-A1 | EFFICIENT AND SCALABLE SYNTHESES OF NICOTINOYL RIBOSIDES AND REDUCED NICOTINOYL RIBOSIDES, MODIFIED DERIVATIVES THEREOF, PHOSPHORYLATED ANALOGS THEREOF, ADENYLYL DINUCLEOTIDE CONJUGATES THEREOF, AND NOVEL CRYSTALLINE FORMS THEREOF | THE QUEEN'S UNIVERSITY OF BELFAST (GB) | 2022-04-07 | — | — | US | disclosed |
| CN-107846883-A | The solvent-free phosphorylation of selectivity | 可劳迈戴斯有限公司 | 2018-03-27 | — | — | CN | disclosed |
| US-7153901-B2 | Low viscosity flame retardants are the reaction product of a mixed ester of tetrabromophthalic acid with diethylene glycol and propylene glycol with an acid anhydride, organic phosphate, or organic chlorophosphate; minimizing visible scorching of the flexible polyurethane foam during its production | ALBEMARLE CORPORATION (US) | 2006-12-26 | — | — | US | disclosed |
| US-20030198992-A1 | By interacting with periplasmic molecular chaperones so the assemlbly of pili is prevented or inhibited and thereby the infectivity of the bacteria is diminished; used in drug design | HULTGREN SCOTT (US) | 2003-10-23 | — | — | US | disclosed |
| US-6596504-B2 | Preventing, inhibiting or enhancing binding between at least one type of pilus subunit and at least one type of periplasmic molecular chaperone in the pilus-forming bacteria for therapy or prophylaxis of diseases | WASHINGTON UNIVERSITY | 2003-07-22 | — | — | US | disclosed |
| US-6548265-B2 | Preventing, inhibiting or enhancing binding between pilus subunits and periplasmic molecular chaperone | WASHINGTON UNIVERSITY | 2003-04-15 | — | — | US | disclosed |
| US-20020146428-A1 | Treatment or prophylaxis of diseases caused by pilus-forming bacteria | HULTGREN SCOTT (US) | 2002-10-10 | — | — | US | disclosed |
| US-6420127-B1 | PREVENTION OF MICROORGANISMAL INFECTIONS; OBTAIN MEMBRANES, INCUBATE WITH MODULATORS, MONITOR MICROORGANISMAL INFECTIONS | WASHINGTON UNIVERSITY | 2002-07-16 | — | — | US | disclosed |
| US-20020045199-A1 | Treatment or prophylaxis of diseases caused by pilus-forming bacteria | HULTGREN SCOTT (US) | 2002-04-18 | — | — | US | disclosed |
| US-6153396-A | DRUG SCREENING BY ADDING COMPOUND TO MIXTURE OF CHAPERONE AND PILUS SUBUNIT AND DETERMINING THE CHANGE IN BINDING; BACTERICIDES FOR URINARY TRACT INFECTIONS | SIGA PHARMACEUTICALS, INC. (US) | 2000-11-28 | — | — | US | disclosed |
| US-6001823-A | NOVEL PYRANOSIDES WHICH ARE BELIEVED TO BE CAPABLE OF INTERACTING WITH PERIPLASMIC MOLECULAR CHAPERONES | WASHINGTON UNIVERSITY | 1999-12-14 | — | — | US | disclosed |
| US-4291024-A | ANTICANCER AGENTS | UNIVERSITY OF RHODE ISLAND | 1981-09-22 | — | — | US | disclosed |
| US-4283394-A | ANTICARCINOGENIC AGENTS | RESEARCH CORPORATION (US) | 1981-08-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250163093-A1 | EFFICIENT AND SCALABLE SYNTHESES OF NICOTINOYL RIBOSIDES AND REDUCED NICOTINOYL RIBOSIDES, MODIFIED DERIVATIVES THEREOF, PHOSPHORYLATED ANALOGS THEREOF, ADENYLYL DINUCLEOTIDE CONJUGATES THEREOF, AND NOVEL CRYSTALLINE FORMS THEREOF | NAPRT, NAMPT, CD38 | LMNA 1649/4885SMN1; SMN2 1687/4885PKM 3353/4885 |
| US-11345720-B2 | Efficient and scalable syntheses of nicotinoyl ribosides and reduced nicotinoyl ribosides, modified derivatives thereof, phosphorylated analogs thereof, adenylyl dinucleotide conjugates thereof, and novel crystalline forms thereof | NAPRT, NAMPT, CD38 | LMNA 1627/4885SMN1; SMN2 1687/4885PKM 3310/4885 |
| US-20020045199-A1 | Treatment or prophylaxis of diseases caused by pilus-forming bacteria | HSP90B1, HSPBP1, PLPBP | LMNA 3006/4885SMN1; SMN2 4228/4885PKM 857/4885 |
| US-20220106350-A1 | EFFICIENT AND SCALABLE SYNTHESES OF NICOTINOYL RIBOSIDES AND REDUCED NICOTINOYL RIBOSIDES, MODIFIED DERIVATIVES THEREOF, PHOSPHORYLATED ANALOGS THEREOF, ADENYLYL DINUCLEOTIDE CONJUGATES THEREOF, AND NOVEL CRYSTALLINE FORMS THEREOF | NAPRT, NAMPT, CD38 | LMNA 1627/4885SMN1; SMN2 1687/4885PKM 3310/4885 |
| US-12195494-B2 | Efficient and scalable syntheses of nicotinoyl ribosides and reduced nicotinoyl ribosides, modified derivatives thereof, phosphorylated analogs thereof, adenylyl dinucleotide conjugates thereof, and novel crystalline forms thereof | NAPRT, NAMPT, CD38 | LMNA 1649/4885SMN1; SMN2 1687/4885PKM 3353/4885 |
| US-20020146428-A1 | Treatment or prophylaxis of diseases caused by pilus-forming bacteria | HSP90B1, HSPBP1, PLPBP | LMNA 3006/4885SMN1; SMN2 4228/4885PKM 857/4885 |
| US-20230391815-A1 | EFFICIENT AND SCALABLE SYNTHESES OF NICOTINOYL RIBOSIDES AND REDUCED NICOTINOYL RIBOSIDES, MODIFIED DERIVATIVES THEREOF, PHOSPHORYLATED ANALOGS THEREOF, ADENYLYL DINUCLEOTIDE CONJUGATES THEREOF, AND NOVEL CRYSTALLINE FORMS THEREOF | NAPRT, NAMPT, CD38 | LMNA 1649/4885SMN1; SMN2 1687/4885PKM 3353/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.